156 related articles for article (PubMed ID: 34349654)
1. Pharmacotherapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria - A Pilot Comparative Study.
Kamusheva M; Dimitrova M; Tachkov K; Petrova G; Mitkova Z
Front Pharmacol; 2021; 12():695181. PubMed ID: 34349654
[TBL] [Abstract][Full Text] [Related]
2. Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece.
Seitaridou Y; Tsekov I; Kamusheva M; Dimitrova M; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):241-246. PubMed ID: 34525887
[TBL] [Abstract][Full Text] [Related]
3. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G
Front Public Health; 2018; 6():61. PubMed ID: 29556491
[TBL] [Abstract][Full Text] [Related]
4. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.
Kostadinov K; Popova-Sotirova I; Marinova Y; Musurlieva N; Iskrov G; Stefanov R
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672571
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria.
Karanyotova S; Topova B; Petrova E; Doychev P; Kapitanska E; Petrova G; Mitkova Z; Dimitrova M
Front Public Health; 2023; 11():1073733. PubMed ID: 36935674
[TBL] [Abstract][Full Text] [Related]
6. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
7. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries.
Kamusheva M; Manova M; Savova AT; Petrova GI; Mitov K; Harsányi A; Kaló Z; Márky K; Kawalec P; Angelovska B; Lakić D; Tesar T; Draganic P; Geitona M; Hatzikou M; Paveliu MS; Männik A
Front Pharmacol; 2018; 9():795. PubMed ID: 30079023
[No Abstract] [Full Text] [Related]
8. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
Iskrov GG; Raycheva RD; Stefanov RS
Folia Med (Plovdiv); 2013; 55(3-4):80-6. PubMed ID: 24712287
[TBL] [Abstract][Full Text] [Related]
9. Availability and reimbursement of biological products for severe asthma in Bulgaria.
Milushewa P; Doneva M; Petrova G
SAGE Open Med; 2020; 8():2050312120951067. PubMed ID: 32922787
[TBL] [Abstract][Full Text] [Related]
10. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
11. Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010-2019.
Foltanova T; Majernik A; Malikova E; Kosirova S
Front Pharmacol; 2022; 13():768325. PubMed ID: 35153774
[No Abstract] [Full Text] [Related]
12. Budgetary Impact of Medicinal Therapies for Rare Diseases in Bulgaria.
Iskrov GG; Jakovljevic MM; Stefanov RS
Folia Med (Plovdiv); 2018 Mar; 60(1):79-91. PubMed ID: 29668449
[TBL] [Abstract][Full Text] [Related]
13. Patient Access to Medicines for Rare Diseases in European Countries.
Detiček A; Locatelli I; Kos M
Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
[TBL] [Abstract][Full Text] [Related]
14. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria.
Iskrov G; Jessop E; Miteva-Katrandzhieva T; Stefanov R
Georgian Med News; 2015 May; (242):46-53. PubMed ID: 26042447
[TBL] [Abstract][Full Text] [Related]
15. Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape.
Kostadinov K; Marinova Y; Dimitrov K; Hristova-Atanasova E; Iskrov G; Stefanov R
Healthcare (Basel); 2024 Feb; 12(4):. PubMed ID: 38391833
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapeutic recommendations for application of target oncological drug therapies for treatment of breast cancer in Bulgaria - therapeutic efficacy and cost effectiveness.
Vekov T; Lebanova H; Grigorov E
J BUON; 2015; 20(6):1420-5. PubMed ID: 26854436
[TBL] [Abstract][Full Text] [Related]
17. Is the pharmaceutical market in Bulgaria innovative?
Stoimenova A; Stankova M; Samev K; Petrova G
Boll Chim Farm; 2003 Sep; 142(7):260-3. PubMed ID: 14677267
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the Household and Health Care System Expenditures in Bulgaria.
Mitkova Z; Petrova G
Front Public Health; 2021; 9():675277. PubMed ID: 34277542
[TBL] [Abstract][Full Text] [Related]
19. How Managed Entry Agreements Influence the Patients' Affordability to Biological Medicines-Bulgarian Example.
Mitkova Z; Manev I; Tachkov K; Boyadzhieva V; Stoilov N; Doneva M; Petrova G
Healthcare (Basel); 2023 Aug; 11(17):. PubMed ID: 37685461
[TBL] [Abstract][Full Text] [Related]
20. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]